Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.
Abadie, Eric; Devogelaer, Jean-Pierre; Ringe, Johann D.et al.
2005 • In Seminars in Arthritis and Rheumatism, 35 (1), p. 1-4
Clinical Trials as Topic; Glucocorticoids/adverse effects; Health Planning Guidelines; Humans; Osteoporosis/chemically induced/drug therapy/prevention & control; Rheumatic Diseases/drug therapy
Abstract :
[en] OBJECTIVES: The Group for the Respect and Excellence in Science (GREES) has reviewed and updated their recommendations for clinical trials to evaluate the efficacy and safety of new chemical entities to be used in the treatment and prevention of glucocorticoid-induced osteoporosis (GIOP). METHODS: Consensus discussion of the committee. RESULTS: With the exception of steroid use posttransplantation, there is no need to differentiate between underlying diseases. Prevention and treatment for GIOP are dependent on exposure to glucocorticoids rather than T-scores as in postmenopausal osteoporosis (PMO). If fracture data are obtained for PMO, it need not be repeated for GIOP, relying instead on bone mineral density (BMD) trials of at least 1 year. GREES recommends several changes in the previous guidance for GIOP. The committee saw no need to repeat preclinical studies if those have been previously done to assure bone quality in PMO. Similarly, phase I and phase II trials, if careful dose selection has been done for PMO, should not be repeated. The "prevention" and "treatment" claims should remain. Since the most recent evidence suggests significant increase in fracture risk for daily doses of prednisone of 5 mg/day or equivalent, clinical trials should concentrate on patients receiving at least this daily dosage. The emergence of bisphosphonates as the reference treatment, together with the rapid bone loss and high fracture incidence in glucocorticoid users, necessitates recommending a noninferiority trial design with lumbar spine BMD as the primary endpoint after 1 year. CONCLUSIONS: Registration of new chemical entities to be used in the management of GIOP should be granted, based on a 1-year noninferiority trial, using BMD as primary outcome and alendronate or risedronate as comparator. Demonstration of antifracture efficacy should have been previously demonstrated in PMO.
Disciplines :
General & internal medicine
Author, co-author :
Abadie, Eric ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Devogelaer, Jean-Pierre
Ringe, Johann D.
Ethgen, Dominique .J
Bouvenot, Gilles M.
Kreutz, Gottfried
Laslop, Andrea
Orloff, John J.
Vanderauwera, Philippe M.
Delmas, Pierre D.
Dere, Willard H.
Branco, Jaime
Altman, Roy D.
Avouac, Bernard P.
Menkes, Charles J.
Vanhaelst, Luc
Mitlak, Bruce H.
Tsouderos, Yannis
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.
Publication date :
2005
Journal title :
Seminars in Arthritis and Rheumatism
ISSN :
0049-0172
eISSN :
1532-866X
Publisher :
W.B. Saunders, Philadelphia, United States - Pennsylvania
T. Van Staa, H.G.M. Leufkens, L. Abenhaim, B. Zhang, C. Cooper Use of oral corticosteroids and risk of fractures J Bone Miner Res 15 2000 993 1000
R.F. Laan, P.L. van Riel, L.B. van de Putte, L.J. van Erning, M.A. van't Hof, J.A. Lemmens Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis - a randomized, controlled-study Ann Intern Med 119 1993 963 968
G. Rizzato, G. Tosi, G. Schiraldi, L. Montemurro, D.S. Sisti Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis Sarcoidosis 5 1988 99 103
M. Luengo, C. Picado, L. Delrio, N. Guanabens, S.W. Banham, I.T. Boyle Vertebral fractures in steroid dependent asthma and involutional osteoporosis - a comparative study Thorax 46 1991 803 806
P.L. Selby, J.P. Halsey, K.R.H. Adams, P. Klimiuk, S.M. Knight, B. Pal Corticosteroids do not alter the threshold for vertebral fracture J Bone Miner Res 15 2000 952 956
T.P. Van Staa, H.G. Leufkens, C. Cooper The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis Osteoporos Int 13 2002 777 787
J.E. Compston, M. Audran, B. Avouac, G. Bouvenot, J.-P. Devogelaer, R. Eastell Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis Calcif Tissue Int 59 1996 323 327
American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Rheum 44 2001 1496-53
R.A. Adler, M.C. Hochberg Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the department of veterans affairs Arch Intern Med 163 2003 2619 2624
S. Epstein Immunosuppressant drugs and bone disease: a clinician's perspective J Clin Densitom 1 1998 317 321
Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998;459-69.
Committee for Proprietary Medicinal Products (CPMP), Efficacy Working Party Note for Guidance on Involutional Osteoporosis in Women CPMP/EWP/552/95, 1999.
Food and Drug Administration (FDA). Preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Washington, DC, April 1994.
C.G. Bellows, A. Ciaccia, J.N.M. Heersche Osteoprogenitor cells in cell population derived from mouse and rat calvaria differ in their response to corticosterone, cortisol, and cortisone Bone 23 1998 119 125
J.L. Ferretti, S.O. Vazquez, C.J. Delgado, R. Capozza, G. Cointry Biphasic dose-response curves of cortisol effects on rat diaphyseal bone biomechanics Calcif Tissue Int 50 1992 49 54
M. Li, Y. Shen, B.P. Halloran, B.D. Baumann, K. Miller, T.J. Wronski Skeletal response to corticosteroid deficiency and excess in growing male rats Bone 19 1996 81 88
T.P. Van Staa, R.F. Laan, I.P. Barton, S. Cohen, D.M. Reid, C. Cooper Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis Rheum 48 2003 3224 3229
J.A. Kanis, H. Johannson, A. Oden, O. Johnell, C. DeLaet, L.J. Melton A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 19 2004 893 899
T.P. Van Staa, H.M.G. Leufkens, L. Abenhaim, B. Zhang, C. Cooper Oral corticosteroids and fracture risk: relationship to daily and cumulative doses Rheumatology 39 2000 1383 1389
K.G. Saag, R. Emkey, T.J. Schnitzer, J.P. Brown, F. Hawkins, S. Goemaere Alendronate for the treatment and prevention of glucorticoid-induced osteoporosis N Engl J Med 339 1998 292 299
S. Cohen, R.M. Levy, M. Keller, E. Boling, R.D. Emkey, M. Greenwald Risedronate therapy prevents corticosteroid-induced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 42 1999 2309 2318
D.M. Reid, R.A. Hughes, R.F. Laan, N.A. Sacco-Gibson, D.H. Wenderoth, S. Adami Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial J Bone Miner Res 15 2000 1006 1020
P. Delmas, G. Calvo, M. Boers, E. Abadie, B. Avouac, A. Kahan, J.M. Kaufman The use of placebo-controlled and non inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis Osteoporos Int 13 2002 1 5
